Non-Steroidal Anti-Inflammatory Pharmaceuticals Market in China 2021

Abstract
The non-steroidal anti-inflammatory pharmaceuticals market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.2% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for non-steroidal anti-inflammatory pharmaceuticals. The China non-steroidal anti-inflammatory pharmaceuticals market is segmented on the basis of type. By type, it is categorized into aspirin, celecoxib, diclofenac sodium, ibuprofen, and others.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Pfizer Inc., Qilu Pharmaceutical Co. Ltd..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-steroidal anti-inflammatory pharmaceuticals market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Type: aspirin, celecoxib, diclofenac sodium, ibuprofen, and others
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the China non-steroidal anti-inflammatory pharmaceuticals market
Pinpoint growth sectors and trends for investment
Understand what the future of the non-steroidal anti-inflammatory pharmaceuticals market in China looks like
Identify the competitive landscape and window of opportunity

Content
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Non-Steroidal Anti-Inflammatory Pharmaceuticals Market by Type
4.1 Aspirin
4.2 Celecoxib
4.3 Diclofenac Sodium
4.4 Ibuprofen
4.5 Others
5. Company Profiles
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Jiangsu Hengrui Medicine Co., Ltd.
5.3 Merck & Co.
5.4 Pfizer, Inc.
5.5 Qilu Pharmaceutical Co., Ltd.
6. Appendix
6.1 About StrategyHelix
6.2 Disclaimer